Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) – A Strong Candidate for Growth Investors

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) stands out as a compelling pick for investors following Louis Navellier’s growth-focused strategy. The company meets several key criteria outlined in The Little Book That Makes You Rich, demonstrating strong fundamentals and growth potential.

Key Strengths Based on Navellier’s Criteria

• Positive Earnings Revisions & Surprises: Analysts have raised EPS estimates for the next quarter by 21.67% over the past three months. AUPH has also exceeded earnings expectations in all of the last four quarters, with an average surprise of 197.36%.
• Strong Sales & Earnings Growth: Revenue grew 29.20% year-over-year, while quarterly sales increased 24.18%. EPS surged 171.79% over the past year, with a remarkable 633.33% jump in the most recent quarter.
• Expanding Profitability: Operating margin improved by 154.52% year-over-year, reflecting better cost management alongside revenue growth.
• Robust Cash Flow: Free cash flow grew 198.21% in the past year, indicating financial flexibility and the ability to fund future growth.
• High Return on Equity (ROE): At 11.38%, AUPH’s ROE outperforms 94.28% of its biotechnology peers.

Valuation & Financial Health

Aurinia’s valuation appears reasonable, with a forward P/E of 10.26, well below industry averages. The company also maintains a solid balance sheet, with a healthy current ratio of 5.93 and manageable debt levels.

For a deeper look, review the full fundamental analysis report.

Our Little Book Strategy screener provides more stocks that fit this growth-focused approach.

Disclaimer

This is not investment advice. Always conduct your own research before making investment decisions.